New Directions at Tenet
David Ricker, the new head of group purchasing for Tenet says that one of the first things that led him to take the new job was that, as a for-profit system, Tenet can pursue areas voluntary alliances and pure GPOs can't.
You may also be interested in...
Biogen/Eisai’s US filing of aducanumab for Alzheimer’s has a ripple effect in China, where a leading biomedical researcher has publicly questioned data for the country’s first approved drug for the disease, GV971.
Boston Scientific’s VP of cardiac rhythm management business in Europe, the Middle East and Africa, Angelo De Rosa, talked to Medtech Insight about opportunities to accelerate digital health transformation during the COVID-19 crisis. See what De Rosa said about it here.
Restricting orphan drug approvals could save the US billions of dollars, study from University of California’s Center for Health Policy and Economics suggests.